Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Liabilities and Shareholders Equity (2016 - 2025)

Anaptysbio filings provide 10 years of Liabilities and Shareholders Equity readings, the most recent being $364.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 24.69% year-over-year to $364.4 million, compared with a TTM value of $1.5 billion through Dec 2025, down 18.54%, and an annual FY2025 reading of $364.4 million, down 24.69% over the prior year.
  • Liabilities and Shareholders Equity hit $364.4 million in Q4 2025 for Anaptysbio, up from $353.1 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $643.1 million in Q4 2021, with the low at $335.2 million in Q2 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $468.1 million (2023), compared with a mean of $482.1 million.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 57.7% in 2022, then decreased 28.44% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $643.1 million in 2021, then decreased by 5.08% to $610.4 million in 2022, then fell by 25.88% to $452.4 million in 2023, then grew by 6.95% to $483.8 million in 2024, then dropped by 24.69% to $364.4 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $364.4 million, $353.1 million, and $335.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.